BACKGROUND & AIMS: Wilson disease (WD) is an inherited disorder of copper disposition caused by an ATP7B transporter gene mutation, leading to copper accumulation in predisposed tissues. In addition to a genetic predisposition, other factors are likely to contribute to its clinical manifestation. The aim of the study was to assess whether oxidative stress affects the phenotypic manifestation of WD. METHODS: In 56 patients with WD (29 men; 26 with the hepatic form, 22 with the neurologic form, and eight asymptomatic; mean age 38.5 ± 12 years), total serum antioxidant capacity (TAC) and inflammatory parameters (hs-CRP, IL-1β, IL-2, IL-6, IL-10, and TNF-α) were analyzed and related to the clinical manifestation, and mutations of the ATP7B gene. The control group for the TAC and inflammatory parameters consisted of 50 age- and gender-matched healthy individuals. RESULTS: WD patients had a significantly lower TAC (p < 0.00001), lower IL-10 levels (p = 0.039), as well as both higher IL-1β (p = 0.019) and IL-6 (p = 0.005) levels compared to the control subjects. TNF-α, hs-CRP, and IL-2 did not differ from the controls. Patients with the neurological form of WD had a significantly lower TAC than those with the hepatic form (p < 0.001). In addition, the lower TAC was associated with the severity of the neurological symptoms (p = 0.02). No relationship between the inflammatory parameters and clinical symptoms was found. CONCLUSIONS: Data from our study suggest that the increased oxidative stress contributes significantly to the clinical manifestation of WD; as a lower TAC is associated with the neurological symptoms in WD patients.

1st Faculty of Medicine 4th Department of Internal Medicine Charles University Prague Prague Czech Republic

Zobrazit více v PubMed

Atherosclerosis. 1997 Sep;133(2):139-52 PubMed

Gut. 2007 Jan;56(1):115-20 PubMed

Pediatr Res. 2006 Oct;60(4):472-7 PubMed

N Engl J Med. 2002 Apr 18;346(16):1221-31 PubMed

Am J Pathol. 2008 Dec;173(6):1783-94 PubMed

J Hepatol. 2009 Mar;50(3):555-61 PubMed

Eur J Neurol. 2011 Jan;18(1):184-90 PubMed

Clin Gastroenterol Hepatol. 2005 Aug;3(8):726-33 PubMed

J Hepatol. 2009 Sep;51(3):557-64 PubMed

Eur J Biochem. 1993 Jul 15;215(2):213-9 PubMed

Biochim Biophys Acta. 2000 Apr 6;1474(2):177-82 PubMed

Liver Int. 2003 Jun;23(3):139-42 PubMed

Mol Genet Metab. 2005 Sep-Oct;86(1-2):277-85 PubMed

Hepatology. 2008 Jun;47(6):2089-111 PubMed

Lancet. 2000 Aug 5;356(9228):469-74 PubMed

Nat Genet. 1993 Dec;5(4):344-50 PubMed

Biometals. 2003 Mar;16(1):103-11 PubMed

Neurology. 2005 May 24;64(10):1726-32 PubMed

Semin Liver Dis. 1996 Feb;16(1):3-12 PubMed

J Clin Invest. 2011 Apr;121(4):1508-18 PubMed

N Engl J Med. 1968 Feb 15;278(7):352-9 PubMed

Med Hypotheses. 2009 Dec;73(6):1029-30 PubMed

Liver Int. 2011 Jan;31(1):83-91 PubMed

Eur J Neurol. 2000 Sep;7(5):491-4 PubMed

J Hepatol. 1994 Jan;20(1):41-6 PubMed

Toxicol In Vitro. 2002 Apr;16(2):167-75 PubMed

Methods Enzymol. 1988;158:351-7 PubMed

Pediatr Res. 1995 Feb;37(2):219-26 PubMed

J Rheumatol Suppl. 1981 Jan-Feb;7:90-3 PubMed

Nat Genet. 1993 Dec;5(4):327-37 PubMed

Nat Genet. 1995 Feb;9(2):210-7 PubMed

Brain. 2000 Mar;123 Pt 3:585-90 PubMed

J Neurol Sci. 2005 Feb 15;228(2):121-3 PubMed

Talanta. 1995 Sep;42(9):1195-214 PubMed

Neurotoxicology. 2009 Jul;30(4):605-12 PubMed

Gastroenterology. 1994 Dec;107(6):1788-98 PubMed

J Neurosci. 1999 Feb 1;19(3):1018-26 PubMed

J Hepatol. 2004 Nov;41(5):758-63 PubMed

J Inherit Metab Dis. 2010 Dec;33 Suppl 3:S233-40 PubMed

Ann Intern Med. 1997 Jul 1;127(1):21-6 PubMed

Pediatr Res. 1996 Feb;39(2):259-63 PubMed

World J Gastroenterol. 2008 Apr 21;14(15):2383-7 PubMed

J Toxicol Sci. 2009;34 Suppl 2:SP229-36 PubMed